Response to neoadjuvant chemotherapy in patients with advanced breast cancer: A local hospital experience

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 2, 2010, Pages 303-308

  Khokher, Samina ^a   Mahmood, Saqib ^b   Khan, Saeed Akhtar ^c  

^a INMOL Hospital   (Pakistan)

^b UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^c Poonch Medical College   (Pakistan)

Author keywords

Advanced malignancies; Breast cancer; Clinical response; Neoadjuvant chemotherapy

Indexed keywords

EID: 78650713802     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. American Cancer Society (2008). Breast Cancer Facts 2007. Atlanta, USA.
2. Ardavanis A, Scorilas A, Tryfonopoulas D, et al. (2006). Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin,vinorelbine,and fluorouracil chemotherapy, surgery, and radiotherapy: long term results. Oncologist, 11, 563-73.
3. Aziz Z. (2008). Across generations: cancer treatment in developing countries. J Clin Oncol, 26, 4990-1.
4. Aziz Z, Iqbal J, Akram M. (2008). Effect of social class disparities on disease stage, quality of treatment and survival outcomes in breast cancer patients from developing countries. Breast, 14, 372-5.
5. Azizunisa, Bhurgri Y, Raza F, et al. (2008). Comparison of ER, PR & HER 2/Neu (C-erb B2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev, 9, 553-6.
6. Bear DB, Anderson S, Brown A, et al. (2003).The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide; Preliminary results from National Surgical Adjuvant Breast and Bowel project protocol B27. J Clin Oncol, 21, 4165-74.
7. Bonadonna G, Valagussa P, Brambilla C, et al. (1998).Primary chemotherapy in operable breast cancer: Eight year experience at Milan Cancer Institute. J Clin Oncol, 16, 93-100.
8. Carey LA, Perou CM, Livasy CA, et al. (2006). Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502.
9. Chen S, Chang, Lin Y, et al. (2008). High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with docetaxel and epirubicin. Jpn J Clin Oncol, 38, 99-105.
10. Chia S, Swain SM, Byrd DR, et al. (2008). Locally advanced and inflammatory breast cancer. J Clin Oncol, 26, 786-90.
11. Chopra K. (2001). The Indian scene. J Clin Oncol, 19, 106-11.
12. El Saghir NS, Eniu A, Carlson RW, et al. (2008). Locally advanced breast cancer treatment guideline implementation with particular attention to low and middle income countries. Cancer, 113, 2315-24.
13. Eniu A, Carlson RW, Aziz Z, et al. (2008). Breast cancer in limited resource countries: treatment and allocation of resources. The Breast, 12, S38-53.
14. Fisher B, Bryant J, Wolmark N, et al. (1998). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 16, 2672-85.
15. Garimella V, Watson MB, Cairns H, et al. (2007). Assessment of apoptotic markers as predictors of response to neoadjuvant FEC chemotherapy in locally advanced breast cancer. Cancer Therapy, 5, 239-42.
16. Gianni L, Semiglazov V, Manikhas GM, et al. (2007). Neoadjuvant Trastuzumab in locally advanced breast cancer (NOAH): antitumor and safety analysis. J Clin Oncol, 25 (18 Suppl), 532.
17. Gilani GM, Kamal S, Akhter AS. (2003). A differential study of breast cancer patients in Punjab, Pakistan. J Pak Med Assoc, 53, 478-80.
18. Giordano SH. (2003). Update on locally advanced breast cancer. Oncologist, 8, 521-30.
19. Gralow JR, Zujewski JA, Winer E. (2008). Preoperative therapy in invasive breast cancer: Reviewing the state of the science and exploring new research directions. J Clin Oncol, 26, 696-7.
20. Heys SD, Hutcheon AW, Sarkar TK, et al. (2002) .On behalf of the Aberdeen Breast group. Neoadjuvant Docetaxel in Breast cancer: 3 year survival results from the Aberdeen Trial. Clin Breast Cancer, Suppl 3, 69-74.
21. Ishikawa T, Hamaguchi Y, Ichikawa Y, et al. (2002). Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report. Jpn J Clin Oncol, 32, 64-7.
22. Kuerer HM, Hunt KK, Newman LA, et al. (2000). Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. J Am Coll Surg, 190, 350-63.
23. Kuerer HM, Newman L, Smith T, et al. (1999). Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin based neoadjuvant chemotherapy. J Clin Oncol, 17, 460-9.
24. Lebowitz PF, Eng-Wong J, Swain SM, et al. (2004). A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res, 10, 6764-9.
25. Lee MC, Patel-Parekh L, Bland KI, et al. (2007). Increased frequency of Estrogen Receptor (ER) Negative and Aneuploid Breast Cancer in African American women at all stages of disease: First analysis from the National Cancer Database.(NCDB), Society of Surgical Oncology Breast Cancer Symposium Abstract 121.
26. Linderholm BK, Hellborg H, Johansson U, et al. (2009). Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol, 20, 1639-46.
27. Lyons JA, Silverman P, Remick S, et al. (2006). Toxicity results and early outcome data on a randomized phase II study of Docetaxel + or - Bevacizumab for locally advanced unresectable breast cancer. J Clin Oncol, 24, 3049.
28. Malik IA. (2002). Clinicopathological features of breast cancer in Pakistan. J Pak Med Assoc, 52, 100-4.
29. Mathew J, Asgeirsson KS, Cheung KL, et al. (2009). Neoadjuvant chemotherapy for locally advanced breast cancer. A review of literature and future directions. EJSO, 35, 113-22.
30. Mauriac L, Keshaviah A, Debled M et al. (2007). Predictors of early relapse in postmenopausal women with hormone receptor positive breast cancer in BIG 1-98 trial. Ann Oncol, 18, 859-67.
31. Mauriac L, McGregor G, Avril A. (1999). Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124 month median followup. Ann Oncol, 10, 47-52.
32. Mieog JSD, Vanderhage JA, VandeVelde CJH. (2007). Neoadjuvant chemotherapy for operable breast cancer. Br J Cancer, 94, 1189-200.
33. Miller AB, Hoogstraten B, Staquet M, et al. (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
34. National Comprehensive Cancer Network (2002). Practice Guidelines in Oncology. Breast Version 2. 2002.
35. Newman LA. (2009). Epidemiology of locally advanced breast cancer. Semin Radiat Oncol, 19, 195-203.
36. Rastogi P, Anderson SJ, Bear HD, et al. (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Projects B-18 and B-27. J Clin Oncol, 26, 778-85.
37. RiesFilho JS, Tutt ANJ. (2008). Triple negative tumors: a critical review. Histopathology, 52, 108-18.
38. SEER (2000). National Cancer Institute DCCPS, Surveillance Research Program, Cancer Statistics Branch. SEER Program Public use data tapes 1973-1998, November 2000 submission, issued April 2001.
39. SEER Cancer Statistics Review 1975-2005, National Cancer Institute [http://seer.cancer.gov/csr/1975-2005/].
40. Shenkier T, Weir L, Levine M, et al. (2004). Clinical practice guidelines for the care and treatment of breast cancer: 15. Treatment for women with stage III or locally advanced breast cancer. CMAJ, 170, 983-94.
41. Singletary SE, Allred C, Ashley P, et al. (2002). Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol, 20, 3628-36.
42. Stead LA, Lash TL, Sobieraj JE, et al. (2009) Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res, 11, R18.
43. Therasse P. (2002). Measuring the clinical response. What does it mean? Eur J Cancer, 38, 1817-23.
44. Tiezzi DG, Andrade JM, Ribeiro-Silva A, et al. (2007). Her-2, p53, p21 and hormonal receptors protein expression as predictor factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer, 7, 36.
45. VanderHage JA, VaderHage CJH, Julian J, et al. (2001). Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol, 19, 4224-37.
46. Wolff AC, Berry D, Carey LA, et al. (2008). Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol, 26, 814-9.
47. Wolmark N, Wang J, Mamounas E, et al. (2001). Preoperative chemotherapy in patients with operable breast cancer:nine year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr, 30, 96-102.
48. Yip CH, Taib NAM, Mohamed I. (2006). Epidemiology of breast cancer in Malaysia. Asian Pac J Cancer Prev, 7, 369-74.